MYX – Credit Suisse rates the stock as Downgrade to Neutral from Outperform

By Broker News | More Articles by Broker News

The company has announced a significant deterioration in the performance of its generic products since the first half results because of increased competition and US$4m in one-off adverse items. The high-margin specialty brands revenue is also weaker than expected.

Revenue declined -15% in January to April and gross profit was down -20%. The company is currently reviewing the carrying value of generic assets which could result in an impairment.

Credit Suisse downgrades to Neutral from Outperform and reduces the target to $0.64 from $1.00. The broker envisages merit in the strategy to pivot towards the more stable earnings profile in specialty brands but the outlook for FY20 remains unclear.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $0.64.Current Price is $0.56. Difference: $0.08 – (brackets indicate current price is over target). If MYX meets the Credit Suisse target it will return approximately 12% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →